Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1477-9560
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series ; volume:16 ; number:1 ; day:19 ; month:12 ; year:2018 ; pages:1-7 ; date:12.2018
Thrombosis journal ; 16, Heft 1 (19.12.2018), 1-7, 12.2018

Klassifikation
Medizin, Gesundheit

Urheber
Greenfield, Graeme
McMullin, Mary Frances
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12959-018-0187-z
URN
urn:nbn:de:101:1-2019011622044069926526
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:58 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Greenfield, Graeme
  • McMullin, Mary Frances
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Myeloproliferative neoplasms: The era of JAK2 mutations and more…

Myeloproliferative neoplasms: The era of JAK2 mutations and more…

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms

Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Verbundene Objekte